Targeting IL-6 Trans-Signaling: Amplifying the Benefits of IL-6 Inhibition in Myocardial Infarction

Pål Aukrust^{1

2

3}, Ola Kleveland⁴, Lars Gullestad^{1

5

6}

Affiliations

¹ Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
² Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
³ Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
⁴ Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
⁵ Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
⁶ K.G. Jebsen Cardiac Research Centre and Centre for Heart Failure Research, University of Oslo, Oslo, Norway.

Editorial

Pål Aukrust et al. JACC Basic Transl Sci. 2021.

. 2021 May 24;6(5):444-446.

doi: 10.1016/j.jacbts.2021.01.007. eCollection 2021 May.

Pål Aukrust^{1

2

3}, Ola Kleveland⁴, Lars Gullestad^{1

5

6}

¹ Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
² Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
³ Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
⁴ Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
⁵ Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
⁶ K.G. Jebsen Cardiac Research Centre and Centre for Heart Failure Research, University of Oslo, Oslo, Norway.

No abstract available

Keywords: infarct size; inflammation; interleukin-6; myocardial infarction; myocardial remodeling.

Conflict of interest statement

All authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Selective Interleukin-6 Trans-Signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction.
George MJ, Jasmin NH, Cummings VT, Richard-Loendt A, Launchbury F, Woollard K, Turner-Stokes T, Garcia Diaz AI, Lythgoe M, Stuckey DJ, Hingorani AD, Gilroy DW. George MJ, et al. JACC Basic Transl Sci. 2021 Apr 7;6(5):431-443. doi: 10.1016/j.jacbts.2021.01.013. eCollection 2021 May. JACC Basic Transl Sci. 2021. PMID: 34095633 Free PMC article.

1. Ridker P.M., Everett B.M., Thuren T. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131. - PubMed
1. Kleveland O., Kunszt G., Bratlie M. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37:2406–2413. - PubMed
1. Broch K., Anstensrud A.K., Woxholt S. Interleukin-6 receptor inhibition in acute ST-segment elevation myocardial infarction: a randomized placebo-controlled trial. https://ssrn.com/abstract=3671415 Available at: Accessed January 6, 2021. - PubMed
1. Epelman S., Liu P.P., Mann D.L. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol. 2015;15:117–129. - PMC - PubMed
1. George M.J., Jasmin N.H., Cummings V.T. Selective interleukin-6 trans-signaling blockade is more effective than panantagonism in reperfused myocardial infarction. J Am Coll Cardiol Basic Trans Science. 2021;6:431–443. - PMC - PubMed